An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study.
Crohn's disease, disease‐based
Ulcerative colitis, disease‐based
inflammatory bowel disease, disease‐based
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
09 Jul 2024
09 Jul 2024
Historique:
revised:
04
06
2024
received:
24
04
2024
accepted:
30
06
2024
medline:
9
7
2024
pubmed:
9
7
2024
entrez:
9
7
2024
Statut:
aheadofprint
Résumé
Subcutaneous (SC) formulations of infliximab (IFX) and vedolizumab (VDZ) are approved for the treatment of inflammatory bowel diseases (IBDs). Our aim was to evaluate the effectiveness of switching from intravenous (IV) to SC formulations of IFX and VDZ in IBDs. This multicentre, retrospective study collected data of adult patients with Crohn's disease (CD) or ulcerative colitis (UC) switched to SC IFX or VDZ. The primary endpoint was clinical remission at 12 months stratified based on timing of switch. A composite endpoint consisting of therapy discontinuation, reverse-switch, need for steroids, and drug optimization was evaluated. A multivariate analysis investigated the association between patients' characteristics and outcomes. Two hundred and thirty-one patients (59% UC, 53% male, mean age 44 ± 15 years, 68% IFX) from 13 centres were included. The switch occurred at Week 6 in a third of cases (36%). Median time to switch was 13 months. Most patients switched to SC IFX and VDZ were in clinical remission at 3 (87% and 77%), 6 (86% and 83%) and 12 (63% and 60%) months. In the multivariate analysis, there was no difference in clinical remission rate at 12 months; however, patients switched at Week 6 had a higher rate of experiencing any therapeutic changes at 3 (false discovery rate (FDR) = .002), 6 (FDR <1 × 10 SC IFX and VDZ are effective in daily clinical practice in IBD patients. Switching patients in remission reduces the risk of negative outcomes.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Subcutaneous (SC) formulations of infliximab (IFX) and vedolizumab (VDZ) are approved for the treatment of inflammatory bowel diseases (IBDs). Our aim was to evaluate the effectiveness of switching from intravenous (IV) to SC formulations of IFX and VDZ in IBDs.
METHODS
METHODS
This multicentre, retrospective study collected data of adult patients with Crohn's disease (CD) or ulcerative colitis (UC) switched to SC IFX or VDZ. The primary endpoint was clinical remission at 12 months stratified based on timing of switch. A composite endpoint consisting of therapy discontinuation, reverse-switch, need for steroids, and drug optimization was evaluated. A multivariate analysis investigated the association between patients' characteristics and outcomes.
RESULTS
RESULTS
Two hundred and thirty-one patients (59% UC, 53% male, mean age 44 ± 15 years, 68% IFX) from 13 centres were included. The switch occurred at Week 6 in a third of cases (36%). Median time to switch was 13 months. Most patients switched to SC IFX and VDZ were in clinical remission at 3 (87% and 77%), 6 (86% and 83%) and 12 (63% and 60%) months. In the multivariate analysis, there was no difference in clinical remission rate at 12 months; however, patients switched at Week 6 had a higher rate of experiencing any therapeutic changes at 3 (false discovery rate (FDR) = .002), 6 (FDR <1 × 10
CONCLUSION
CONCLUSIONS
SC IFX and VDZ are effective in daily clinical practice in IBD patients. Switching patients in remission reduces the risk of negative outcomes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14283Informations de copyright
© 2024 The Author(s). European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
Références
Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn's disease: medical treatment. J Crohns Colitis. 2020;14:4‐22.
Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16:2‐17.
Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158:1450‐1461.
Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. Gastroenterology. 2021;160:2496‐2508.
Anon. Infliximab data sheet—Cerca con Google. Accessed December 17, 2023. https://www.google.it/search?q=infliximab+data+sheet&sca_esv=591624743&sxsrf=AM9HkKl59GSpVOrGMp4PJ2yt5TVof1cPVQ%3A1702804490026&ei=Crx‐ZfSLAYmO9u8P0Jym6AQ&oq=infliximab+and+data+s&gs_lp=Egxnd3Mtd2l6LXNlcnAiFWluZmxpeGltYWIgYW5kIGRhdGEgcyoCCAEyBhAAGBYYHjIGEAAYFhgeMggQABgWGB4YD0jzU1D9N1iERHACeAGQAQCYAWagAZcGqgEDOS4xuAEByAEA‐AEBwgIKEAAYRxjWBBiwA8ICChAAGIAEGBQYhwLCAgUQABiABMICCBAAGIAEGMsB4gMEGAAgQYgGAZAGCA&sclient=gws‐wiz‐serp
Anon. Vedolizumab data sheet—Cerca con Google. Accessed December 17, 2023. https://www.google.it/search?q=vedolizumab+data+sheet&sca_esv=591624743&sxsrf=AM9HkKlW3f‐xJPdY_6ljnojqUvtllxV44w%3A1702804505083&ei=Gbx‐ZcDOBPKE9u8P‐OCjsAk&oq=veedolizumdata+sheet&gs_lp=Egxnd3Mtd2l6LXNlcnAiFHZlZWRvbGl6dW1kYXRhIHNoZWV0KgIIADIGEAAYHhgNMggQABgIGB4YDUjiI1DrBli_GHACeAGQAQCYAYEBoAHBCaoBAzYuNrgBAcgBAPgBAcICBBAAGEfCAgoQABhHGNYEGLADwgIGEAAYBxgewgINEAAYgAQYDRixAxixA8ICBxAAGIAEGA3CAggQIRigARjDBMICChAhGKABGMMEGAriAwQYACBBiAYBkAYF&sclient=gws‐wiz‐serp
Schreiber S, Ben‐Horin S, Leszczyszyn J, et al. Randomized controlled trial: subcutaneous vs intravenous infliximab CT‐P13 maintenance in inflammatory bowel disease. Gastroenterology. 2021;160:2340‐2353.
Sandborn WJ, Baert F, Danese S, et al. Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158:562‐572.e12.
Vermeire S, D'Haens G, Baert F, et al. Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn's disease: results from the VISIBLE 2 randomised trial. J Crohns Colitis. 2022;16:27‐38.
Remy C, Caron B, Gouynou C, et al. Inflammatory bowel disease patients' acceptance for switching from intravenous infliximab or vedolizumab to subcutaneous formulation: the Nancy experience. J Clin Med. 2022;11:7296.
Patil I. Visualizations with statistical details: the “ggstatsplot” approach. J Open Source Software. 2021;6:3167.
Wickham H, Averick M, Bryan J, et al. Welcome to the tidyverse. J Open Source Software. 2019;4:1686.
Jr FEH, functions CD contributed several functions and maintains latex. Hmisc: Harrell miscellaneous. 2023 Accessed March 1, 2024. https://cran.r‐project.org/web/packages/Hmisc/
Therneau TM. TL original S‐>R port and R maintainer until, Elizabeth a, et al. survival: survival analysis. 2009 Accessed March 11, 2024. https://cran.r‐project.org/web/packages/survival/
Kassambara A, Kosinski M, Biecek P, et al. survminer: drawing survival curves using “ggplot2.”. 2021 Accessed March 11, 2024. https://cran.r‐project.org/web/packages/survminer/
Huguet JM, García‐Lorenzo V, Martí L, et al. Subcutaneous infliximab [CT‐P13], a true biologic 2.0. Real clinical practice multicentre study. Biomedicine. 2022;10:2130.
Buisson A, Nachury M, Reymond M, et al. Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: the REMSWITCH study. Clin Gastroenterol Hepatol. 2023;21:2338‐2346. e3.
Smith PJ, Critchley L, Storey D, et al. Efficacy and safety of elective switching from intravenous to subcutaneous infliximab [CT‐P13]: a multicentre cohort study. J Crohns Colitis. 2022;16:1436‐1446.
Parisio L, Settanni CR, Varca S, et al. Effectiveness and safety of switching from intravenous to subcutaneous vedolizumab formulation in inflammatory bowel disease patients in clinical remission. J Gastrointestin Liver Dis. 2023;32:452‐459.
Kubesch A, Kruse N, Jungheim F, et al. Switching vedolizumab from IV to SC injection in inflammatory bowel disease patients with active disease: real‐world experience from a German IBD cohort. J Clin Med. 2023;12:7657.
Lim SH, Gros B, Sharma E, et al. Safety, effectiveness, and treatment persistence of subcutaneous vedolizumab in IBD: a multicenter study from the United Kingdom. Inflamm Bowel Dis. 2023;izad166.
Ribaldone DG, Parisio L, Variola A, et al. Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: the SVEDO study, an IG‐IBD study. Dig Liver Dis. 2024;56:77‐82.
Wiken TH, Høivik ML, Buer L, et al. Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring. Scand J Gastroenterol. 2023;58:863‐873.
Volkers A, Straatmijer T, Duijvestein M, et al. Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases. Aliment Pharmacol Ther. 2022;56:1044‐1054.
Buisson A, Nachury M, Bazoge M, et al. Long‐term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: the REMSWITCH‐LT study. Aliment Pharmacol Ther. 2024;59:526‐534.
Marsal J, Barreiro‐de Acosta M, Blumenstein I, Cappello M, Bazin T, Sebastian S. Management of non‐response and loss of response to anti‐tumor necrosis factor therapy in inflammatory bowel disease. Front Med (Lausanne). 2022;9:897936.
Hong SN, Song JH, Kim SJ, et al. One‐year clinical outcomes of subcutaneous infliximab maintenance therapy compared with intravenous infliximab maintenance therapy in patients with inflammatory bowel disease: a prospective cohort study. Inflamm Bowel Dis. 2023;30:izad094.
Harno‐Tasihin J, Siregar L, Paajanen M, Arkkila P, Punkkinen J. Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses. Scand J Gastroenterol. 2023;59:1‐8.
Burdge G, Hardman A, Carbery I, Broglio G, Greer D, Selinger CP. Uptake of a switching program for patients receiving intravenous infliximab and vedolizumab to subcutaneous preparations. J Clin Med. 2022;11:5669.
D'Amico F, Solitano V, Aletaha D, et al. Biobetters in patients with immune‐mediated inflammatory disorders: an international Delphi consensus. Autoimmun Rev. 2021;20:102849.
Hilley P, Wong D, Ma R, Peterson A, de Cruz P. Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease: what is the opportunity cost of improving access to healthcare? Intern Med J. 2024;54:970‐979.
Fierens L, Liefferinckx C, Hoefkens E, et al. Introduction of subcutaneous infliximab CT‐P13 and vedolizumab in clinical practice: a multi‐stakeholder position statement highlighting the need for post‐marketing studies. J Crohns Colitis. 2022;16:1059‐1069.
Jharap B, Sandborn WJ, Reinisch W, et al. Randomised clinical study: discrepancies between patient‐reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis. Aliment Pharmacol Ther. 2015;42:1082‐1092.
Colombel J‐F, Keir ME, Scherl A, et al. Discrepancies between patient‐reported outcomes, and endoscopic and histological appearance in UC. Gut. 2017;66:2063‐2068.
Lichtenstein L, Ron Y, Kivity S, et al. Infliximab‐related infusion reactions: systematic review. J Crohns Colitis. 2015;9:806‐815.
Checkley A, Kristofek L, Bolgar W. P065 vedolizumab related infusion reactions in inflammatory bowel disease patients treated in an alternate care setting. Gastroenterology. 2019;156:S44‐S45.
Admin S. European Crohn's and colitis organisation—ECCO—P591 negative impact of high body mass index on the efficacy of anti‐TNFα agents in patients with inflammatory bowel disease. Accessed June 4, 2024. https://www.ecco‐ibd.eu/publications/congress‐abstracts/item/p591‐negative‐impact‐of‐high‐body‐mass‐index‐on‐the‐efficacy‐of‐anti‐tnf‐agents‐in‐patients‐with‐inflammatory‐bowel‐disease.html
D'Haens G, Reinisch W, Schreiber S, et al. Subcutaneous infliximab monotherapy versus combination therapy with immunosuppressants in inflammatory bowel disease: a post hoc analysis of a randomised clinical trial. Clin Drug Investig. 2023;43:277‐288.
Roblin X, Nancey S, Papamichael K, et al. Higher serum infliximab concentrations following subcutaneous dosing are associated with deep remission in patients with inflammatory bowel disease. J Crohns Colitis. 2023;18:jjad188.